Literature DB >> 26335394

COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance.

R Poorani1, Anant N Bhatt2, B S Dwarakanath2, Undurti N Das3.   

Abstract

Polyunsaturated fatty acids (PUFAs) are vital for normal growth and development and physiological function of various tissues in humans. PUFAs have immunomodulatory actions in addition to their ability to modulate inflammation, vascular reactivity, neurotransmission and stem cell biology. PUFAs and their metabolites possess both pro- and anti-inflammatory properties that underlie their actions and involvement in several diseases. Aspirin, a non-steroidal anti-inflammatory drug (NSAID), possesses both cyclo-oxygenase (COX) and lipoxygenase (LOX) inhibitory action and enhances the production of anti-inflammatory lipoxin A4 {(called as epi-lipoxin A4, aspirin-triggered lipoxins (ATLs))}. In addition, at low doses aspirin may not interfere with the production of prostacyclin (PGI2). Both lipoxin A4 and PGI2 have vasodilator, platelet anti-aggregator and anti-inflammatory actions that may underlie the beneficial actions of aspirin. Paradoxically, other NSAIDs may not have the same actions as that of aspirin on PUFA metabolism. Similar anti-inflammatory compounds are formed from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by the action of aspirin termed as resolvins (from EPA and DHA) and protectins and maresins from DHA. PUFAs: arachidonic acid (AA), EPA and DHA and their various products modulate not only inflammation and immune response but also possess actions on various genes, nuclear factors, cyclic AMP and GMP, G-protein coupled receptors (GPRs), hypothalamic neurotransmitters, hormones, cytokines and enzymes, and interact with nitric oxide, carbon monoxide, and hydrogen sulfide to regulate their formation and action and to form new compounds that have several biological actions. These pleiotropic actions of PUFAs and their metabolites may explain their ability to play a role in several physiological actions and diseases. The big challenge is to harness these actions to prevent and manage clinical conditions.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspirin; Lipoxins; Nitric oxide; Polyunsaturated fatty acids; Prostaglandins; Resolvins

Mesh:

Substances:

Year:  2015        PMID: 26335394     DOI: 10.1016/j.ejphar.2015.08.049

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

1.  Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas.

Authors:  Veronika Fedirko; Gail McKeown-Eyssen; Charles N Serhan; Elizabeth L Barry; Robert S Sandler; Jane C Figueiredo; Dennis J Ahnen; Robert S Bresalier; Douglas J Robertson; Carlton W Anderson; John A Baron
Journal:  Mol Carcinog       Date:  2017-03-06       Impact factor: 4.784

2.  In utero exposure to fine particulate matter results in an altered neuroimmune phenotype in adult mice.

Authors:  Joshua A Kulas; Jordan V Hettwer; Mona Sohrabi; Justine E Melvin; Gunjan D Manocha; Kendra L Puig; Matthew W Gorr; Vineeta Tanwar; Michael P McDonald; Loren E Wold; Colin K Combs
Journal:  Environ Pollut       Date:  2018-05-22       Impact factor: 8.071

3.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

4.  Pharmacokinetics of omega-3 fatty acids in patients with severe sepsis compared with healthy volunteers: A prospective cohort study.

Authors:  Radhika Parikh; Jason H T Bates; Matthew E Poynter; Benjamin T Suratt; Polly E Parsons; C Lawrence Kien; Daren K Heyland; Karen I Crain; Julie Martin; Jayanthi Garudathri; Renee D Stapleton
Journal:  Clin Nutr       Date:  2019-04-09       Impact factor: 7.324

Review 5.  Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases.

Authors:  Undurti N Das
Journal:  Eur J Clin Nutr       Date:  2022-06-14       Impact factor: 4.016

Review 6.  Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

Authors:  Martin D Rosenthal; Jayshil Patel; Kyle Staton; Robert G Martindale; Frederick A Moore; Gilbert R Upchurch
Journal:  Curr Gastroenterol Rep       Date:  2018-08-04

Review 7.  Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.

Authors:  Bian Wu; Giorgio Mottola; Melinda Schaller; Gilbert R Upchurch; Michael S Conte
Journal:  Mol Aspects Med       Date:  2017-08-04

8.  Changes in erythrocyte membrane epoxyeicosatrienoic, dihydroxyeicosatrienoic, and hydroxyeicosatetraenoic acids during pregnancy.

Authors:  Selina T Somani; Maxwell Zeigler; Emily E Fay; Maggie Leahy; Bethanee Bermudez; Rheem A Totah; Mary F Hebert
Journal:  Life Sci       Date:  2020-10-15       Impact factor: 5.037

Review 9.  Pro-resolving lipid mediators in vascular disease.

Authors:  Michael S Conte; Tejal A Desai; Bian Wu; Melinda Schaller; Evan Werlin
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

10.  A rat model to investigate quality of recovery after abdominal surgery.

Authors:  Juan P Cata; Miguel Patiño; Michael J Lacagnina; Jiahe Li; Aysegul Gorur; Ruben Agudelo-Jimenez; Bo Wei; Carin A Hagberg; Patrick M Dougherty; Imad Shureiqi; Peiying Yang; Peter M Grace
Journal:  Pain Rep       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.